Most cases of genital herpes are due to herpes simplex virus (HSV)-2. The rate of HSV-2 infections increased by 30% from 1988 to 1994. In addition to genital herpes, transmission of HSV-2 to neonates causes severe life-threatening infections. HSV-2 infection also increases the risk of transmission and infection with HIV. Thus a vaccine for HSV-2 would not only reduce the rate of genital herpes, but also might reduce spread of HIV. Several HSV-2 vaccines have been tested in humans for prevention or reduction of genital herpes disease. A vaccine containing a single viral protein (HSV-2 glycoprotein D) recently showed no evidence for protection against genital herpes in a large international, phase three, randomized controlled trial in HSV-2 seronegative women. We postulate that the limited efficacy of the HSV-2 glycoprotein D vaccine is likely due to inadequate induction of broadly neutralizing antibody and cellular immune responses. We cloned the entire HSV-2 genome into a plasmid containing a bacterial artificial chromosome BAC). We showed that virus derived from the HSV-2 BAC replicated in cell culture at the same rate as wild-type virus and that mice infected with virus derived from the HSV-2 BAC developed disease as well as latent HSV-2 infection at a similar rate as animals infected with wild-type virus. We have engineered mutations in the HSV-2 BAC and have obtained HSV-2 with mutations in the viral glycoprotein D (gD) that are critical for the interaction of gD with one of its receptors, nectin-1, but not with another receptor, HVEM. Since HVEM is expressed on epithelial cells and lymphocytes, while nectin-1 is expressed on neurons and epithelial cells, the HSV-2 gD mutant would be predicted to be impaired for infecting neurons, but not epithelial cells and therefore might induce a potent immune response, but not cause neurologic disease in animals.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Cohen, Jeffrey I (2018) Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-? Syndrome. Front Immunol 9:237
Wang, Kening; Tomaras, Georgia D; Jegaskanda, Sinthujan et al. (2017) Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice J Virol 91:
Cohen, Jeffrey I (2017) Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2. J Infect Dis 215:844-846
Odegard, Jared M; Flynn, Patrick A; Campbell, David J et al. (2016) A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine 34:101-9
Wang, Kening; Goodman, Kyle N; Li, Daniel Y et al. (2016) A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. J Virol 90:562-74
Lamers, Susanna L; Newman, Ruchi M; Laeyendecker, Oliver et al. (2015) Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. J Virol 89:8206-18
Çuburu, Nicolas; Wang, Kening; Goodman, Kyle N et al. (2015) Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge. J Virol 89:83-96
Newman, Ruchi M; Lamers, Susanna L; Weiner, Brian et al. (2015) Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol 89:8219-32
Knipe, David M; Corey, Lawrence; Cohen, Jeffrey I et al. (2014) Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on ""Next Generation Herpes Simplex Virus Vaccines"". Vaccine 32:1561-2
Ben-Sasson, S Z; Wang, K; Cohen, J et al. (2013) IL-1? strikingly enhances antigen-driven CD4 and CD8 T-cell responses. Cold Spring Harb Symp Quant Biol 78:117-24

Showing the most recent 10 out of 15 publications